Janux Therapeutics, Inc. Common Stock
JANX Real Time Price USDRecent trades of JANX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by JANX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens Jan. 17, 2023
-
Patent Title: Cleavable linker compositions and methods Nov. 29, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of JANX in WallStreetBets Daily Discussion
Recent insights relating to JANX
Recent picks made for JANX stock on CNBC
ETFs with the largest estimated holdings in JANX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view JANX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.